Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Despite advancements in cancer immunotherapy, most lymphomas remain unresponsive to checkpoint inhibitors. P-selectin glycoprotein ligand-1 (PSGL-1), recently identified as a promoter of T cell exhaustion in melanoma murine models, has emerged as a novel immune checkpoint protein and promising immunotherapeutic target. In this study, we investigated the potential of PSGL-1 antibody targeting in B-cell lymphoma. Using allogeneic coculture systems, we demonstrated that targeted antibody interventions against human PSGL-1 resulted in enhancement of T cell activation and effector cytokine production in response to lymphoma cells. Moreover, in vitro treatment of primary lymphoma cell suspensions with PSGL-1 antibody resulted in increased activation of autologous lymphoma-infiltrating T cells. Finally, using a syngeneic B-cell lymphoma mouse model, we found that PSGL-1 antibody treatment significantly slowed tumor development and reduced endpoint tumor burden. This anti-tumoral action was accompanied by augmented tumor infiltration with CD4 + and CD8 + T cells and reduced infiltration with regulatory T cells. These results demonstrate that PSGL-1 antibody blockade bolsters T-cell activity against B-cell lymphoma, suggesting a potential novel immunotherapeutic approach to treat these malignancies.
